Heart 1998;79:121-127 ( February )

Review

Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy

C M Newman,^a A Price,^b D W Davies,^c T A Gray,^b A P Weetman^a

^a Section of Medicine, University of Sheffield Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK, ^b Department of Clinical Chemistry, Northern General Hospital, ^c Department of Cardiology, St Mary's Hospital, London W2 1NY, UK

Correspondence to: Dr Newman.

Accepted for publication 3 October 1997

The first 150 words of the full text of this article appear below.

	Introduction

Amiodarone is a highly effective agent for the prophylaxis and treatment of many cardiac rhythm disturbances, ranging from paroxysmal atrial fibrillation to life threatening ventricular tachyarrhythmias.¹ Unlike many other antiarrhythmic drugs, amiodarone appears to be safe in patients with significant left ventricular dysfunction,^2-5 and may confer prognostic benefit in some patient subgroups.^6,7

Amiodarone bears a remarkable structural resemblance to thyroid hormones. The free base contains 39% iodine by weight (fig 1), and chronic treatment is associated with 40-fold increases in plasma and urinary iodide levels.⁸ Amiodarone has complex effects on thyroid physiology in all patients taking the drug, and chronic treatment is associated with substantial changes in the results of standard thyroid function tests. Although most patients remain clinically euthyroid, a significant minority (up to 15% of patients in the UK and the USA) develop amiodarone induced hypothyroidism or thyrotoxicosis.^9-12 Unfortunately, amiodarone induced thyroid dysfunction is rarely manageable by . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bogazzi, F., Tomisti, L., Rossi, G., Dell'Unto, E., Pepe, P., Bartalena, L., Martino, E. (2009). Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study. J. Clin. Endocrinol. Metab. 94: 3757-3762 [Abstract] [Full Text]  
• Yiu, K.-H., Jim, M.-H., Siu, C.-W., Lee, C.-H., Yuen, M., Mok, M., Shea, Y.-F., Fan, K., Tse, H.-F., Chow, W.-H. (2009). Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome. J. Clin. Endocrinol. Metab. 94: 109-114 [Abstract] [Full Text]  
• McMurray, J., Petrie, M., Swedberg, K., Komajda, M., Anker, S., Gardner, R. (2009). CHAPTER 23 Heart Failure. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Rehman, H. u., Kurnik, D., Loebstein, R., Olchovsky, D., Coceani, M., Skolnik, N., Armon, C., Zimetbaum, P. (2007). Amiodarone for Atrial Fibrillation. NEJM 356: 2424-2426 [Full Text]  
• Bogazzi, F., Bartalena, L., Tomisti, L., Rossi, G., Tanda, M. L., Dell'Unto, E., Aghini-Lombardi, F., Martino, E. (2007). Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations. J. Clin. Endocrinol. Metab. 92: 556-562 [Abstract] [Full Text]  
• Rubinstein, J., Zimetbaum, P. J., Josephson, M. E., Schlegel, A., Desai, K. R., Singh, B. N., Singh, S. N., Reda, D. (2005). Amiodarone versus sotalol for atrial fibrillation.. NEJM 353: 627-630 [Full Text]  
• Hermida, J.-S., Tcheng, E., Jarry, G., Moullart, V., Arlot, S., Rey, J.-L., Delonca, J., Schvartz, C. (2004). Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. Europace 6: 169-174 [Abstract] [Full Text]  
• (2003). Using oral amiodarone. DTB 41: 9-12 [Abstract] [Full Text]  
• Pitt, A. D, Fernandes, C., Bewick, N. L, Hemsworth, P. D, Buhagiar, K. A, Hansen, P. S, Rasmussen, H. H, Delbridge, L., Whalley, D. W (2003). Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone. Cardiovasc Res 57: 101-108 [Abstract] [Full Text]  
• PINTO, A., GLICK, M. (2002). Management of patients with thyroid disease: Oral health considerations. Journal of the American Dental Association 133: 849-858 [Abstract] [Full Text]  
• Osman, F., Franklyn, J. A., Sheppard, M. C., Gammage, M. D. (2002). Successful Treatment of Amiodarone-Induced Thyrotoxicosis. Circulation 105: 1275-1277 [Abstract] [Full Text]  
• Martino, E., Bartalena, L., Bogazzi, F., Braverman, L. E. (2001). The Effects of Amiodarone on the Thyroid. Endocr. Rev. 22: 240-254 [Abstract] [Full Text]  
• Toft, A D, Boon, N A (2000). GENERAL CARDIOLOGY: Thyroid disease and the heart. Heart 84: 455-460 [Full Text]  
• Loh, K.-C. (2000). Current concepts in medicine: Amiodarone-induced thyroid disorders: a clinical review. Postgrad. Med. J. 76: 133-140 [Abstract] [Full Text]